The 36-month beta value for VRCA is at 1.66. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for VRCA is 49.69M, and currently, shorts hold a 5.73% of that float. The average trading volume for VRCA on April 15, 2025 was 396.21K shares.
VRCA) stock’s latest price update
Verrica Pharmaceuticals Inc (NASDAQ: VRCA)’s stock price has gone rise by 14.24 in comparison to its previous close of 0.48, however, the company has experienced a -14.33% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-04-02 that WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Gavin Corcoran, M.D.
VRCA’s Market Performance
VRCA’s stock has fallen by -14.33% in the past week, with a monthly rise of 2.90% and a quarterly drop of -12.93%. The volatility ratio for the week is 22.48% while the volatility levels for the last 30 days are 18.89% for Verrica Pharmaceuticals Inc The simple moving average for the past 20 days is 8.72% for VRCA’s stock, with a -73.47% simple moving average for the past 200 days.
Analysts’ Opinion of VRCA
Needham gave a rating of “Buy” to VRCA, setting the target price at $10 in the report published on July 25th of the previous year.
VRCA Trading at -7.59% from the 50-Day Moving Average
After a stumble in the market that brought VRCA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.15% of loss for the given period.
Volatility was left at 18.89%, however, over the last 30 days, the volatility rate increased by 22.48%, as shares sank -15.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.62% lower at present.
During the last 5 trading sessions, VRCA fell by -14.33%, which changed the moving average for the period of 200-days by -92.16% in comparison to the 20-day moving average, which settled at $0.5084. In addition, Verrica Pharmaceuticals Inc saw -21.01% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRCA starting from Hayes Christopher G., who sale 4,315 shares at the price of $0.65 back on Mar 17 ’25. After this action, Hayes Christopher G. now owns 176,458 shares of Verrica Pharmaceuticals Inc, valued at $2,805 using the latest closing price.
Hayes Christopher G., the CHIEF LEGAL OFFICER of Verrica Pharmaceuticals Inc, sale 26,183 shares at $2.66 during a trade that took place back on Aug 26 ’24, which means that Hayes Christopher G. is holding 115,303 shares at $69,647 based on the most recent closing price.
Stock Fundamentals for VRCA
Current profitability levels for the company are sitting at:
- -8.71 for the present operating margin
- 0.64 for the gross margin
The net margin for Verrica Pharmaceuticals Inc stands at -10.12. The total capital return value is set at -2.62. Equity return is now at value -1546.58, with -112.44 for asset returns.
Based on Verrica Pharmaceuticals Inc (VRCA), the company’s capital structure generated 1.27 points at debt to capital in total, while cash flow to debt ratio is standing at -1.33. The debt to equity ratio resting at -4.66. The interest coverage ratio of the stock is -7.0.
Currently, EBITDA for the company is -65.9 million with net debt to EBITDA at 0.01. When we switch over and look at the enterprise to sales, we see a ratio of 6.66. The receivables turnover for the company is 98.26for trailing twelve months and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.76.
Conclusion
In conclusion, Verrica Pharmaceuticals Inc (VRCA) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
